Bloomberg analysis suggests that high prices for popular shots aren’t necessary to offset research spending.
Robert Langreth and Tanaz MeghjaniWegovy was approved in 2021 for treating obesity. Photographer: Carsten Snejbjerg/Bloomberg -- Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the drugmaker’s entire research budget for the past three decades, undercutting a key argument for their unusually high prices.
The pharma industry has long argued that it needs big windfalls from successful drugs to offset the cost of many experimental treatments that fail during testing. Bloomberg’s findings suggest that this argument is running out of steam for Novo’s popular shots. Sanders said last week that Ozempic could be profitably produced for less than $100 a month, based on his conversations with generic-drug manufacturers, far less than Ozempic’s $968.52 list price. One study suggested the drug could even be made for less than $5 a month.
US government spending on Ozempic and similar drugs for Medicare patients has surged in recent years, according to the health policy organization KFF. A Novo executive said last week that Ozempic will “very likely” be one of the drugs targeted for price cuts in the next round of Medicare negotiations.
Company News Biotech & Pharma General Government Health Care Industry Legal North America Politics Top News Unites States World Top World
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nicotine pouches scarce after federal ban restricts sales to pharmacy-only salesIt’s been just over a week since the federal government banned nicotine pouches from being sold anywhere other than a pharmacy.
Read more »
Hims & Hers offers compounded Wegovy for $99 a month to select professionsU.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients...
Read more »
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reportsPart of 2022's Inflation Reduction Act allows Medicare to negotiate prices for prescription drugs that had been particularly expensive for the federal health...
Read more »
Quebec pilot project will determine if public health insurance will cover Ozempic for obesityThis photograph taken on February 23, 2023, in Paris, shows the anti-diabetic medication 'Ozempic' (semaglutide) made by Danish pharmaceutical company 'Novo Nordisk'.
Read more »
Lottie Moss Warns Against Ozempic Misuse After SeizureModel Lottie Moss has spoken out about the dangers of misusing the diabetes drug Ozempic, revealing she experienced severe dehydration, vomiting, and a seizure after taking it for weight loss. She urges people to reconsider its use outside of medical prescription.
Read more »
Model Shares Warning After Overdose On Ozempic: “Worst Decision I Ever Made”“I hope that by talking about this, it can maybe be a lesson to some people that it’s not worth it.”
Read more »